The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor

Cardiovascular Research

Volumn 59, Issue 4, 2003, Pages 824-833

  Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Coronary heart disease; Endothelium; Nitric oxide; Oxidative stress; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIOXIDANT; ARGININE; BIOLOGICAL MARKER; CITRULLINE; CONJUGATED ESTROGEN; CYANOCOBALAMIN; DIMETHYLAMINE; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; METFORMIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PYRIDOXINE; ROSIGLITAZONE; S ADENOSYLMETHIONINE;

AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONCENTRATION RESPONSE; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME METABOLISM; EXCRETION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY CONCENTRATING CAPACITY; METABOLISM; METHYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; URINARY EXCRETION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

AMIDOHYDROLASES; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE SYNTHASE; RISK FACTORS;

EID: 0842347848     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00500-5     Document Type: Review

References (84)

1. Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J. Am. Med. Assoc. 256:1986;2823-2828.
2. Stampfer M.J., Hu F.B., Manson J.E., Rimm E.B., Willett W.C. Primary prevention of coronary heart disease in women through diet and lifestyle. New Engl. J. Med. 343:2000;16-22.
3. Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? Nephrol. Dial. Transplant. 15:2000;454-456.
4. Pearson T.A. New tools for coronary risk assessment. What are their advantages and limitations? Circulation. 105:2002;886-892.
5. Vane J.R., Anggard E.E., Botting R.M. Regulatory functions of the vascular endothelium. New Engl. J. Med. 323:1990;27-36.
6. Förstermann U., Closs E.I., Pollock J.S., et al. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension. 23:1994;1121-1131.
7. Wolf A., Zalpour C., Theilmeier G. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J. Am. Coll. Cardiol. 29:1997;479-485.
8. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA. 88:1991;4651-4655.
9. Böger R.H., Bode-Böger S.M., Kienke S., et al. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis. 136:1998;67-77.
10. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1989;1774-1777.
11. Böger R.H., Bode-Böger S.M., Mügge A., et al. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284.
12. Hogg N., Kalyanaraman B., Joseph J., Struck A., Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett. 334:1993;170-174.
13. Cooke J.P., Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med. 48:1997;489-509.
14. Rees D.D., Palmer R.M.J., Schulz R., Hodson H.F., Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 101:1990;746-752.
15. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet. 339:1992;572-575.
16. G-dimethyl- arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. Biol. Chem. 245:1970;5751-5758.
17. G′-dimethylarginine in the rabbit. Biochem. J. 154:1976;179-184.
18. Böger R.H., Bode-Böger S.M., Tsao P.S., et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J. Am. Coll. Cardiol. 36:2000;2287-2295.
19. Kurose I., Wolf R., Grisham M.B., Granger D.N. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am. J. Physiol. 268:1995;H2224-H2231.
20. Faraci F.M., Brian J.E., Heistad D.D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am. J. Physiol. 269:1995;H1522-H1527.
21. Segarra G., Medina P., Ballester R.M., et al. Effects of some guanidino compounds on human cerebral arteries. Stroke. 30:1999;2206-2211.
22. Vallance P., Leone A., Calver A., Collier J., Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20:(Suppl 12):1992;S60-S62.
23. G-dimethylarginine by human endothelial cells. Endothelium. 1:1993;137-140.
24. Tsikas D., Sandmann J., Böger R.H., et al. Assessment of nitric oxide synthase activity by gas chromatography-mass spectrometry. J. Chromatogr. B. 742:2000;143-153.
25. Klatt P., Schmidt K., Uray G., Mayer B. Multiple catalytic functions of brain nitric oxide synthase. J. Biol. Chem. 268:1994;14781-14787.
26. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA. 95:1998;9220-9225.
27. Pritchard K.A., Groszek L., Smalley D.M., et al. Native low-density lipoprotein increases endothelial nitric oxide synthase generation of superoxide anion. Circ. Res. 77:1995;510-518.
28. MacAllister R.J., Fickling S.A., Whitley G.S.J., Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br. J. Pharmacol. 112:1994;43-48.
29. Rawal N., Rajpurohit R., Lischwe M.A., et al. Structural specificity of substrate for S-adenosylmethionine:protein arginine N-methyltransferases. Biochim. Biophys. Acta. 1248:1995;11-18.
30. Böger R.H., Sydow K., Borlak J., et al. Cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 87:2000;99-105.
31. Azuma H., Sato J., Hamasaki H., et al. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br. J. Pharmacol. 115:1995;1001-1004.
32. MacAllister R.J., Parry H., Kimoto M., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119:1996;1533-1540.
33. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 99:1999;3092-3095.
34. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am. J. Physiol. 269:1995;C750-C756.
35. Kielstein J.T., Bode-Böger S.M., Frölich J.C., Haller H., Böger R.H. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int. 59:(Suppl 78):2001;S9-S13.
36. MacAllister R.J., Rambausek M.H., Vallance P., et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol. Dial. Transplant. 11:1996;2449-2452.
37. Kielstein J.T., Böger R.H., Bode-Böger S.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 10:1999;594-600.
38. Cross J.M., Donald A.E., Vallance P., et al. Dialysis improves endothelial function in humans. Nephrol. Dial. Transplant. 16:2001;1823-1829.
39. G-dimethyl-L-arginine to L-citrulline in rats. Biochem. Biophys. Res. Commun. 148:1987;671-677.
40. Leiper J.M., Santa Maria J., Chubb A., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343:1999;209-214.
41. Murray-Rust J., Leiper J., McAllister M., et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nature Struct. Biol. 8:2001;679-683.
42. Stühlinger M.C., Tsao P.S., Her J.H., et al. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation. 104:2001;2569-2575.
43. Leiper J., Murray-Rust J., McDonald N., Vallance P. S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc. Natl. Acad. Sci. USA. 99:2002;13527-13532.
44. Achan V., Tran C.T., Arrigoni F., et al. All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ. Res. 90:2002;764-769.
45. Bode-Böger S.M., Böger R.H., Kienke S., Junker W., Frölich J.C. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Res. Commun. 219:1996;598-603.
46. Böger R.H., Bode-Böger S.M., Brandes R.P., et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits - comparison with lovastatin. Circulation. 96:1997;1282-1290.
47. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 98:1998;1842-1847.
48. Böger R.H., Bode-Böger S.M., Thiele W., et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 95:1997;2068-2074.
49. Surdacki A., Nowicki M., Sandmann J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33:1999;652-658.
50. Usui M., Matsuoka H., Miyazaki H., et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 62:1998;2425-2430.
51. Stühlinger M., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J. Am. Med. Assoc. 287:2002;1420-1426.
52. Lundman P., Eriksson M.J., Stühlinger M., et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J. Am. Coll. Cardiol. 38:2001;111-116.
53. Gorenflo M., Zheng C., Werle E., Fiehn W., Ulmer H.E. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J. Cardiovasc. Pharmacol. 37:2001;489-492.
54. Böger R.H., Bode-Böger S.M., Thiele W., et al. Restoring vascular NO formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 32:1998;1336-1344.
55. Zoccali C., Bode-Böger S.M., Mallamaci F., et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet. 358:2001;2113-2117.
56. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am. J. Cardiol. 88:2001;1201-1203.
57. Petersson A., Hedner T., Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet. Gynecol. Scand. 77:1998;808-813.
58. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
59. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. New Engl. J. Med. 329:1993;2002-2012.
60. Böger R.H., Bode-Böger S.M., Frölich J.C. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis. 127:1996;1-11.
61. Schächinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906.
62. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954.
63. Miyazaki H., Matsuoka H., Cooke J.P. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation. 99:1999;1141-1146.
64. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128:1998;262-269.
65. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Project. New Engl. J. Med. 340:1999;14-22.
66. Zoccali C., Benedetto F.A., Maas R., et al. Asymmetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13:2002;490-496.
67. Zoccali C., Mallamaci F., Maas R., et al. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62:2002;339-345.
68. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 358:2001;2127-2128.
69. Nijveldt R.J., Teerlink T., Van der Hoven B., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin. Nutr. 22:2003;23-30.
70. Teerlink T., Nijveldt R.J., de Jong S., van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal. Biochem. 303:2002;131-137.
71. Fard A., Tuck C.H., Donis J.A., et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 20:2000;2039-2044.
72. Ito A., Egashira K., Narishige T., Muramatsu K., Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn. Circ. J. 65:2001;775-778.
73. Delles C., Schneider M.P., John S., Gekle M., Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G),N(G)-dimethylarginine in human essential hypertension. Am. J. Hypertens. 15:2002;590-593.
74. Asagami T., Abbasi F., Stühlinger M., et al. Metformin lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 51:2002;843-846.
75. Teerlink T., Neele S.J., DeJong S., Netelenbos J.C., Stehouwer C.D. Oestrogen replacement therapy lowers plasma levels of asymmetric dimethylarginine in healthy postmenopausal women. Clin. Sci. 105:2003;67-71.
76. Holven K.B., Haugstad T.S., Holm T., et al. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br. J. Nutr. 89:2003;359-363.
77. Sydow K., Schwedhelm E., Arakawa N., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res. 57:2003;244-252.
78. Chan J.R., Böger R.H., Bode-Böger S.M., et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler. Thromb. Vasc. Biol. 20:2000;1040-1046.
79. Rector T.S., Bank A.J., Mullen K.A., et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation. 93:1996;2135-2141.
80. Ceremuzynksi L., Chamiec T., Herbacynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am. J. Cardiol. 80:1997;331-333.
81. Maxwell A.J., Anderson B.E., Cooke J.P. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc. Med. 5:2000;11-19.
82. Cross J.M., Donald A.E., Kharbanda R., et al. Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int. 60:2001;2318-2323.
83. Walker H.A., McGing E., Fisher I., et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina. J. Am. Coll. Cardiol. 38:2001;499-505.
84. Tsikas D., Böger R.H., Sandmann J., Bode-Böger S.M., Frölich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett. 23810:2000;1-3.